Applications: |
Immunodepletion/Immunocompetition |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
RIC8A Blocking Peptide for STJ502777 is synthetically produced from the 500-535 sequence and is suitable for use in western blot applications. |
Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Gene Symbol: |
RIC8A |
Gene ID: |
60626 |
Uniprot ID: |
RIC8A_HUMAN |
Immunogen Region: |
500-535 |
Specificity: |
This blocking peptide is recommended for use in combination with RIC8A antibody, STJ502777 |
Immunogen: |
Synthetic peptide taken within amino acids 500-535 on RIC8A protein |
Post Translational Modifications | Phosphorylated at Ser-436 and Thr-441 by CK2, stabilizing its interface with G alpha proteins. |
Function | Chaperone that specifically binds and folds nascent G alpha proteins prior to G protein heterotrimer formation, promoting their stability and activity: folds GNAI1, GNAO1, GNA13 and GNAQ. Does not fold G(s) G-alpha proteins GNAS nor GNAL. Also acts as a guanine nucleotide exchange factor (GEF) for G alpha proteins by stimulating exchange of bound GDP for free GTP. Involved in regulation of microtubule pulling forces during mitotic movement of chromosomes by stimulating G(i)-alpha protein (GNAI1), possibly leading to release G(i)-alpha-GTP and NuMA proteins from the NuMA-GPSM2-G(i)-alpha-GDP complex. Also acts as an activator for G(q)-alpha (GNAQ) protein by enhancing the G(q)-coupled receptor-mediated ERK activation. |
Peptide Name | Chaperone Ric-8aSynembryn-A |
Cellular Localisation | CytoplasmCell Cortex |
Alternative Peptide Names | Chaperone Ric-8a proteinSynembryn-A proteinRIC8A protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance